The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) via monoclonal antibodies (mAb), is a recent approach offering an additional treatment option for high-or very high-risk patients with hypercholesterolemia not reaching the LDL-C targets despite oral treatment. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.